Conversation with The Cancer Letter

Agios Pharmaceuticals Inc., the sponsor of two drugs that may change the outcomes for a subset of acute myelogenous leukemia patients, is focused on more than AML.

As the landscape in acute myelogenous leukemia changes, consultations with top-tier experts have become a necessity, said John Byrd, the principal investigator of Beat AML, Distinguished University Professor, the D. Warren Brown Professor of Leukemia Research at The Ohio State University, a member of the NCI Leukemia Steering Committee, chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology.

I have been following Vinay Prasad's work for several years, agreeing with some of what he said, but never quite finding time to look carefully at his argumentation.

The practice-changing TAILORx trial was brought to you by publicly funded cancer clinical trials system, pointing to its continuing relevance, said Jeff Abrams, NCI acting director for clinical research and associate director of the Cancer Therapy Evaluation Program.